Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987891 | 0.79 | — | — | |
| SCHEMBL9751463 | 0.73 | ALDH1A1 (0.36) | — | |
| SCHEMBL1702595 | 0.73 | MAOA (0.31) | — | |
| SCHEMBL5168618 | 0.72 | OPRM1 (0.31) | OPRM1OPRK1OPRL1 | |
| SCHEMBL5274311 | 0.70 | OPRM1 (0.33) | OPRM1OPRK1OPRL1 | |
| Bromide SCHEMBL29801969 | 0.69 | OPRM1 (0.32) | OPRM1OPRK1OPRL1 | |
| SCHEMBL5274478 | 0.67 | ALDH1A1 (0.31) | OPRM1OPRK1OPRL1 | |
| SCHEMBL5280804 | 0.67 | MAOB (0.39) | — | |
| SCHEMBL7551055 | 0.67 | PNMT (0.39) | — | |
| SCHEMBL5276695 | 0.67 | ALDH1A1 (0.38) | OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0759922-A1 | NEW ANTAGONIST COMPOUNDS | Astra Aktiebolag (SE) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031463-A1 | NEW ANTAGONIST COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1995-11-23 | — | — | WO | claimed |
| EP-1755604-B1 | USE OF OPIOID RECEPTOR ANTAGONIST COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF DISEASES ASSOCIATED WITH THE TARGET CALCINEURIN | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2009-10-14 | — | — | EP | disclosed |
| CN-100368414-C | Morphinan derivatives, their quaternary ammonium salts substituted at position 14, process for their preparation and their use | HELMUT SCHMIDHAMMER (AT) | 2008-02-13 | — | — | CN | disclosed |
| US-20070167474-A1 | Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin | CHIRONWELLS GMBH (AT) | 2007-07-19 | — | — | US | disclosed |
| EP-1755604-A2 | USE OF OPIOID RECEPTOR ANTAGONIST COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF DISEASES ASSOCIATED WITH THE TARGET CALCINEURIN | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005107752-A2 | USE OF OPIOID RECEPTOR ANTAGONIST COMPOUNDS FOR THE PREVENTION AND/OR TREATMENT OF DISEASES ASSOCIATED WITH THE TARGET CALCINEURIN | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2005-11-17 | — | — | WO | disclosed |
| EP-1595541-A1 | Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2005-11-16 | — | — | EP | disclosed |
| CN-1665819-A | Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof | HELMUT SCHMIDHAMMER (AT) | 2005-09-07 | — | — | CN | disclosed |
| US-6136817-A | Opioid receptor antagonist compounds | ASTRA AB (SE) | 2000-10-24 | — | — | US | disclosed |
| US-5886001-A | Agonist compounds | ASTRA AB (SE) | 1999-03-23 | — | — | US | disclosed |
| EP-0759923-A1 | NEW AGONIST COMPOUNDS | Astra Aktiebolag (SE) | 1997-03-05 | — | — | EP | disclosed |
| EP-0759922-A1 | NEW ANTAGONIST COMPOUNDS | Astra Aktiebolag (SE) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031463-A1 | NEW ANTAGONIST COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995031464-A1 | NEW AGONIST COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1995-11-23 | — | — | WO | disclosed |
| US-4390699-A | NARCOTIC ANTAGONIST | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1983-06-28 | — | — | US | disclosed |
| US-4388463-A | 6-Keto-morphinan analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1983-06-14 | — | — | US | disclosed |
| US-4012435-A | (5,8-DIHYDRO-5,8-ENDOMETHYLENE-1-NAPHTHYL)- CARBAMATES; PESTICIDES | CIBA-GEIGY AG (CH) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167474-A1 | Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin | PPP3R1, OPRK1, OPRM1 | VNN1 2640/4885OPRM1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.